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ABSTRACT
Objective To test the efficacy of supplemental vitamin D
and active forms of vitamin D with or without calcium in
preventing falls among older individuals.
Data sources We searched Medline, the Cochrane central
register of controlled trials, BIOSIS, and Embase up to
August 2008 for relevant articles. Further studies were
identified by consulting clinical experts, bibliographies,
and abstracts. We contacted authors for additional data
when necessary.
ReviewmethodsOnlydoubleblindrandomisedcontrolled
trials of older individuals (mean age 65 years or older)
receiving a defined oral dose of supplemental vitamin D
(vitamin D3 (cholecalciferol) or vitamin D2 (ergocalciferol))
or an active form of vitamin D (1α-hydroxyvitamin D3 (1α-
hydroxycalciferol) or 1,25-dihydroxyvitamin D3 (1,25-
dihydroxycholecalciferol)) and with sufficiently specified
fall assessment were considered for inclusion.
Results Eight randomised controlled trials (n=2426) of
supplemental vitamin D met our inclusion criteria.
Heterogeneity among trials was observed for dose of
vitamin D (700-1000 IU/day v 200-600 IU/day; P=0.02)
and achieved 25-hydroxyvitamin D3 concentration (25
(OH)D concentration: <60 nmol/l v ≥60 nmol/l; P=0.005).
High dose supplemental vitamin D reduced fall risk by
19% (pooled relative risk (RR) 0.81, 95% CI 0.71 to 0.92;
n=1921 from seven trials), whereas achieved serum 25
(OH)D concentrations of 60 nmol/l or more resulted in a
23%fallreduction(pooledRR0.77,95%CI0.65to0.90).
Falls werenot notably reducedbylow dose supplemental
vitamin D (pooled RR 1.10, 95% CI 0.89 to 1.35; n=505
fromtwotrials)orbyachievedserum25-hydroxyvitaminD
concentrations of less than 60 nmol/l (pooled RR 1.35,
95% CI 0.98 to 1.84). Two randomised controlled trials
(n=624) of active forms of vitamin D met our inclusion
criteria.ActiveformsofvitaminDreducedfallriskby22%
(pooled RR 0.78, 95% CI 0.64 to 0.94).
Conclusions Supplemental vitamin D in a dose of 700-
1000 IU a day reduced the risk of falling among older
individualsby19%andtoasimilardegreeasactiveforms
ofvitaminD.DosesofsupplementalvitaminDoflessthan
700 IU or serum 25-hydroxyvitamin D concentrations of
less than 60 nmol/l may not reduce the risk of falling
among older individuals.
INTRODUCTION
Each year one in three people aged 65 years or older
experiences at least one fall,
1-3 with 9% of falls leading
to an emergency room visit and 5-6% resulting in a
fracture.
4Fallpreventionhas,therefore,becomeapub-
lichealthgoal,especiallyastheolderproportionofthe
population grows.
Vitamin D has direct effects on muscle strength
modulated by specific vitamin D receptors present in
humanmuscletissue.
56Myopathyfromseverevitamin
D deficiency presents as muscle weakness and pain,
7
but is reversible with vitamin D supplementation.
6 In
several trials of older individuals at risk for vitamin D
deficiency, vitamin D supplementation improved
strength, function, and balance in a dose-related
pattern.
489Most importantly, these benefits translated
into a reduction in falls.
489
Overall, however, results have been mixed for fall
prevention with vitamin D; for example, several trials
ofvitaminDhavehadnon-significantresults.Thismay
be explained in part by the use of low doses of vitamin
D,assuggestedbya2004meta-analysisoflimiteddata
from three trials on supplemental vitamin D.
10 Other
potential explanations include the availability of vita-
minDoverthecounterforthecontrolgroup;theuseof
an open trial design, which biases trial results towards
thenull
11;andincompleteassessment,inadequatedefi-
nition, or incomplete ascertainment of falls during the
entire observation period,
12 again introducing a bias
towards the null.
Several trials on vitamin D have been performed
since 2004; thus, the importance of vitamin D dose
for the prevention of falls should be reassessed. Speci-
fically, we need to establish the optimum threshold of
serum 25-hydroxyvitamin D3 (25(OH)D; calcidiol
(25-hydroxycholecalciferol)) required to prevent falls
in older individuals. Notably, two epidemiology stu-
dies among older individuals have found a dose-
response relationship between lower extremity func-
tion and serum 25(OH)D concentrations,
1314 with
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optimal function.
13 The other larger study found that
functioncontinuedtoimprovewithincreasingconcen-
tration, without any plateau.
14
Both active forms of vitamin D and standard supple-
mental vitamin D have been suggested to prevent falls
among older individuals, but no direct comparison of
thesetwogroupsisavailable.ActiveformsofvitaminD
do not need hydroxylation in the kidney, so their effect
onfalls should be influenced less by agerelated decline
in kidney function than the effect of supplemental vita-
min D. However, active forms of vitamin D cost more
andareassociatedwithahigherriskforhypercalcaemia
than standard supplemental vitamin D.
The aim of this meta-analysis was to assess the effi-
cacy of vitamin D supplementation, with and without
calcium, for the prevention of falls among older per-
sons by dose and serum concentration of 25(OH)D
achieved.Inaddition,weassessedtheefficacyofactive
forms of vitamin D compared with supplemental vita-
min D in the prevention of falls.
METHODS
Search strategy and data extraction
We conducted a systematic search for all English and
non-English articles in Medline (Ovid, Pubmed) and
the Cochrane central register of controlled trials from
January1960toAugust2008,inBIOSISfromJanuary
1985toJuly2008,andinEmbasefromJanuary1991to
August 2008. Additional studies were identified by
contacting experts, searching reference lists, and
searching abstracts presented at the American Society
forBoneandMineralResearchfrom1995to2008.We
used Medical Subject Headings (MeSH) as search
terms, including terms related to trials (“randomised
controlled trial,”“ controlled clinical trial,”“ random
allocation,”“ double-blind method,” and “single-blind
method”), vitamin D (“cholecalciferol,”“ hydroxy-
cholecalciferol,”“ calcifediol,”“ ergocalciferol,”“ calci-
diol,”“ vitamin D/blood/25-hydroxyvitamin D,”
“1,25-dihydroxyvitamin D,”“ 1-α-hydroxyvitamin
D,”“1-alpha-hydroxyvitaminD,”“calcitriol,”“alfacal-
cidol,”and“paricalcitol”),andfalls(“falls,”“accidental
falls,”“ fall prevention,” and “balance”), and the terms
“humans,”“ elderly,” and “bone density.” Data extra-
ction was conducted independently by two authors
(HAB-F and JH). A consensus procedure was devel-
oped but was not necessary because of concordance.
Inclusion criteria
Randomised controlled trials of fall prevention with a
defined oral dose of supplemental vitamin D (vitamin
D3 (cholecalciferol) or vitamin D2 (ergocalciferol))
or oral active vitamin D (1α-hydroxyvitamin D3
(1α-hydroxycalciferol) or 1,25-dihydroxyvitamin D3
(1,25-dihydroxycholecalciferol)) in individuals aged
65 years or older with a minimum follow-up of three
months were identified. To be included in the primary
analysis,thetrialdesignhadtobedoubleblindandthe
assessment of falls sufficiently specified according to
the following criteria: (a) falls had to be a primary or
secondary end point defined at the onset of the trial;
(b) the study had to include a definition of falls and
how they were assessed;and (c) falls had to be assessed
for the entire trial period. Eligible studies that did not
meetthecriteriafortheprimaryanalysiswereincluded
in a sensitivityanalysis,such asstudiesinvolving older
patients in an unstable health state (that is, those
recruited during acute inpatient care).
We excluded reviews, trials that were not rando-
mised,trialsthatdidnotincludeacontrolgroup,obser-
vational studies, and animal studies. Given that health
conditionsthatplacepatientsathighriskforfallsmight
mask the benefits of vitamin D on falls, we excluded
studies that focused on patients with Parkinson’s dis-
ease, organ transplant recipients, or patients with
stroke. We excluded trials that assessed intramuscular
injection of vitamin D because this technique is inva-
sive and has resulted in small but variable increases in
25(OH)D concentrations.
15
Outcome measures
Our primary outcome measure was the relative risk of
having at least one fall among persons receiving vita-
min D with or without calcium compared with the risk
among those individuals receiving placebo or calcium
supplementation alone. We analysed separately the
effect of supplemental vitamin D and active forms of
vitaminD,andevaluatedbothdoseand25(OH)Dcon-
centrations achieved for supplemental vitamin D.
Quality assessment
We examined the following methodological features
most relevant to the control of bias: randomisation;
Articles identified (n=164)
Potentially relevant articles identified
and screened for retrieval (n=32)
RCTs retrieved for more detailed evaluation (n=20)
Potentially appropriate RCTs to be
included in meta-analysis (n=17)
RCTs included in meta-analysis (n=10):
  Studied vitamin D2 or vitamin D3 (n=8)
  Studied active vitamin D (n=2)
Excluded by screening of titles and abstracts (n=132)
Excluded (n=12):
  Review article (n=10)
  Not an RCT (n=2)
RCTs excluded (n=3):
  Did not have fall outcome (n=1)
  Included patients who had experienced a stroke (n=1)
  Included intra-muscular vitamin D (n=1)
RCTs excluded from meta-analysis (n=7):
  Insufficient fall assessment (n=3)
  Open design or after acute hospitalisation (n=4)
(all 7 included in sensitivity analysis)
Fig 1 | Quorum flow chart. RCT=randomised controlled trial
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and withdrawals.
1617 Given that vitamin D is available
over the counter, trials had to be double blind to be
included in the primary analysis. Open design trials
that met the general eligibility criteria were included
in the sensitivity analysis.
Differences in vitamin D assays
Interlaboratory and interassay variation limit com-
parison between trials for achieved 25(OH)D
concentrations,
1819 with competitive protein binding
assays tending to yield higher concentrations than
radioimmunoassays.
20Toaccountforthesevariations,
we adjusted the 25(OH)D values from the two studies
where a competitive protein binding assay was used to
radioimmunoassayequivalentvalues,accordingtothe
method described by Lips and colleagues.
20
Statistical methods
Outcomeswereanalysedonanintentiontotreatbasisby
using random effect models.
21 In addition, we calculated
t h ed i f f e r e n c ei nr e l a t i v er i s k st od e t e r m i n et h en u m b e r
needed to treat to prevent a person from falling.
Heterogeneityamong studies was explored by prede-
fined covariates using the Q statistic as a test (significant
for P<0.10).
22 The presence of heterogeneity suggests
that the studies should not be pooled because of signifi-
cant differences in results.
23 In such cases, we explored
heterogeneity by dose of vitamin D and 25(OH)D con-
centration achieved by using visual inspection and ran-
dom effect meta-regression analysis. Additional
subgroupanalysesundertakenforsupplementalvitamin
D included type of vitamin D (D2v D3), gender, age (<
80 years v≥80 years), treatment duration (<12 months v
≥12months),levelofindependence(independentvinsti-
tutionalised), and additional calcium supplementation.
To evaluate publication bias, we used Begg’st e s ta n d
Egger’stestwithalleighttrialsfromtheprimaryanalysis
or all 15 trials from the sensitivity analysis.
24 Statistical
analysis was performed with STATA version 8.0 (Stata-
Corp, College Station, TX, USA).
Box 1 Fall ascertainment in trials with supplemental vitamin D included in the primary
analysis
Broe et al, 2007
w1
Falls were defined as “a sudden, unintentional change in position causing a resident to fall
on the ground.” Nursing staff filled out an incident report at the time of the event, the
primary care physician verified it, and the information was entered into the incident report
database.
Bischoff-Ferrari et al, 2006
w2
Falls were defined as “unintentionally coming to rest on the ground, floor, or other lower
level.”Participants were asked to send a postcard after every fall, which was then followed
by a telephone call from a staff member to assess the circumstances of the fall. In
addition, falls were ascertained at every follow-up visit (every six months).
Prince et al, 2008
w3
Falls were defined as “unintentionally coming to rest on the ground, floor, or other lower
level.” Patients were interviewed by study staff every six weeks via telephone or during
clinic visits. The number of falls that had occurred in the previous six weeks and the
associated features of the falls were recorded on a questionnaire.
Flicker et al, 2005
w4
Falls were defined as “an event that results in a person coming to rest inadvertently on the
ground or other lower level.” Residential care staff recorded falls continuously in diaries,
and these were mailed monthly to the central study centre.
Pfeifer et al, 2008
w5
Af a l lw a sd e f i n e da s“falling on to the floor or ground, or hitting an object like a chair or
stair.” Not included as falls were controlled or intentional movements towards a chair or
bed or a near fall in which the participant caught oneself before falling on to the floor or
ground. The number of falls was recorded in fall diaries—each day the participants had to
make a cross in the diary depending on whether a fall had occurred or not. Every two
months, the study participants were also asked via telephone interviews whether a fall
had happened.
Bischoff et al, 2003
w6
Falls were defined as “unintentionally coming to rest on the ground, floor, or other lower
level.” Coming to rest against furniture or a wall was not counted as a fall. Falls were
recorded by nurses on the inpatient units who had received training in the use of the fall
protocol (which included recording date, time, circumstances, and injuries).
Pfeifer et al, 2000
w7
Af a l lw a sd e f i n e da s“falling on to the floor or ground or hitting an object like a chair or
stair.”Notincludedasfallswerecontrolledorintentionalmovementstowardachairorbed
or a near fall in which the participant caught herself before falling on to the floor or ground.
The number of falls was recorded by questionnaires throughout the trial period.
Graafmans et al, 1996
w8
Af a l lw a sd e f i n e da s“unintentionally coming to rest at a lower level or on the ground.”
Participants were asked to record in a diary any falls they had during a 28-week period.
Every week, participants registered whether or not they had fallen, as well as the location,
time, and circumstances of each fall.
Prince et al
w3
Broe et al
w1
Flicker et al
w4
Bischoff-Ferrari et al
w2
Pfeifer et al
w5
Bischoff et al
w6
Pfeifer et al
w7
Combined
Broe et al
w1
(200 IU D2/day)
Broe et alw1
(400 IU D2/day)
Broe et alw1
(600 IU D2/day)
Graafmans et alw8
Combined
Relative risk (95% CI) High dose vitamin D
0.5 0 5 0.1 10
Favours
supplemental
vitamin D
Favours
control
Low dose vitamin D
Pooled relative
risk (95% CI)
0.81 (0.71 to 0.92)
Pooled relative
risk (95% CI)
1.10 (0.89 to 1.35)
Fig 2 |Fall prevention with high dose (700-1000 IU a day) and
low dose (200-600 IU a day) of supplemental vitamin D. Boxes
represent relative risks, and the size of the boxes is
proportional to the size of the high dose supplemental
vitamin D trials included in the primary analysis. Error bars
represent 95% confidence intervals. Shaded boxes indicate
trials with vitamin D3, and white boxes indicate those with
vitamin D2
RESEARCH
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A total of 164 articles were found in our initial search,
132 of which could be excluded by screening the titles
and abstracts (fig 1). A further 12 articles were
excluded either because they did not detail rando-
mised controlled trials or they were review articles.
Ten more trials were excluded because they did not
meet the inclusion criteria so that 10 randomised trials
were included in the final analysis—eight that studied
either vitamin D2 or vitamin D3 and two that assessed
active forms of vitamin D.
Trials assessing supplemental vitamin D
We identified eight randomised controlled trials of
supplementalvitaminD thatmet ourinclusioncriteria
(box 1).
w1-w8 All trials assessed vitamin D treatment for
the prevention of falls as a primary or secondary out-
come and were identified through our MeSH term
Table 1 |Randomised controlled trials of supplemental vitamin D included in the primary analyses
Number of
participants
Age (years;
mean (SD))
Sample
population
Treatment
(daily dose)
Adher-
ence
Study duration
(months)
25(OH)D serum concentration (mmol/l; mean (SD))
Treatmentgroup Control group Assay used
High dose trials
Broe et al, 2007
w1 48
(36 women,
12 men)
89 (5) Nursing home
patients
800IUvitaminD2orplacebo 98% 5 54(23)to75(15)
at 5 months
(n=17). DiaSorin
equivalent mean
values:43to60at
5m o n t h s
53 (29) to 55-60
at 5 months
(n=20). DiaSorin
equivalent mean
values: 42 to 48
Competitive
protein binding
assay
Bischoff-Ferrari et
al, 2006
w2
445
(246 women,
199 men)
71 (5) Ambulatory
individuals
700 IU vitamin D3 +5 0 0m g
calcium (citrate malate) or
placebo
93% 36 76 (35) to 107
(38)at36months
(n=182).DiaSorin
equivalent mean
values: 67 to 95
73(32)to72(30)
at 36 months
(n=195).DiaSorin
equivalent mean
values: 65 to 64
Competitive
protein binding
assay
Prince et al,
2008
w3
302 women 77 (5) Patients with
history of falling
recruited from
emergency
departments, the
electoral roll, and
receiving home
nursing services.
1000IUvitaminD2+500mg
calcium (calcium carbonate)
or500mgcalcium+placebo
8 6 % 1 2 4 5t o6 0a t
12 months
44.3 to 49 at
12 months
Radioimmunoas-
say
Flicker et al,
2005
w4
625
(593 women,
32 men)
83 (8) Residental care
patients
Initially10000IUD2weekly,
then 1000 IU D2 +6 0 0m g
calciumorplacebo+600mg
calcium (calcium carbonate)
68% 24 25-60 at
baseline:(89%of
participants). No
follow-up
25-60 at baseline
(89% of
participants). No
follow-up
Radioimmunoas-
say
Pfeifer et al,
2008
w5
242
(121 women,
121 men)
77 (4) Ambulatory
individuals
800IUvitaminD3+1000mg
calcium or 1000 mg calcium
+ placebo
80% 20 55.4 (18.5) to
84.5 (18.0) at
12 months
(n=122)
53.8 (18.4) to
56.6 (20) at
12 months
(n=120)
Radioimmunoas-
say
Bischoff et al,
2003
w6
122 women 85 (7) Institutionalised
patients
800IUvitaminD3+1200mg
calcium or 1200 mg calcium
+ placebo
100% 3 30.8 (23-55) to
65.5 (49.8-82.8)
at 3 months
(n=45)
29(23-55)to28.5
(24.5-41.5) at
3m o n t h s( n =44)
Radioimmunoas-
say
Pfeifer et al,
2000
w7
137 women 74 (1) Community
dwelling
individuals
800IUvitaminD3+1200mg
calcium or 1200 mg calcium
+ placebo
96% 2withtreatment
plus 10 without
treatment
25.7 (13.6) to
66.1 (33.1) at
2m o n t h s( n =70)
24.6 (12.1) to
42.9 (33.1) at
2m o n t h s( n =67)
Radioimmunoas-
say
Low dose trials
Broe et al, 2007
w1 51
(39 women,
12 men)
92 (6) Nursing home
patients
200IUvitaminD2orplacebo 98% 5 45(23)to60(20)
at 5 months
follow-up (n=24).
Diasorin
equivalent mean
values: 36 to 48
50(23)to61(34)
at 5 months
(n=23). Diasorin
equivalent mean
values: 40 to 49
Competitive
protein binding
assay
Broe et al, 2007
w1 50
(38 women,
12 men)
88 (5) Nursing home
patients
400IUvitaminD2orplacebo 98% 5 53(28)to55(22)
at 5 months
(n=24). Diasorin
equivalent mean
values: 42 to 44
50(23)to61(34)
at 5 months
(n=23). Diasorin
equivalent mean
values: 40 to 49
Competitive
protein binding
assay
Broe et al, 2007
w1 50
(37 women,
13 men)
89 (6) Nursing home
patients
600IUvitaminD2orplacebo 98% 5 40(19)to60(20)
at 5 months
(n=23). Diasorin
equivalent mean
values: 32 to 48
50(23)to61(34)
at 5 months
(n=23). Diasorin
equivalent mean
values: 40 to 49
Competitive
protein binding
assay
Graafmans et al,
1996
w8
354
(302 women,
52 men)
83 (6) Ambulatory
patientsinhomes
and apartments
for older
individuals
400 IU vitamin D3 +
estimated calcium intake
from dairy products (800-
1000 mg/d)
85% 7 Not defined Not defined Not defined
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whichtheauthorsprovidedadditionaldataforthefour
trial arms (200, 400, 600, and 800 international units
(IU) D2v placebo).
w1
Table 1showsthecharacteristicsoftheeightdouble
blind randomised controlled trials with sufficient fall
assessmentincludedinourstudy,includingonerando-
misedcontrolledtrialwithfourstudyarms.
w1Theeight
trials involved 2426 individuals in total, 81% of whom
were women, and participants had an approximate
mean age of 80 years. All participants were in stable
health and were living in the community or in nursing
homes. Vitamin D3 was used in five studies and vita-
minD2inthreestudies.VitaminD2orD3wasgivenin
a daily dose ranging from 200 IU to 1000 IU. Treat-
ment duration varied from 2 months to 36 months.
Calcium supplementation was used in both treatment
and placebo groups in five randomised controlled
trials, and the dose varied between 500 mg/day and
1200 mg/day. In one study, calcium was provided
only in the treatment group, and vitamin D alone was
comparedwithplacebointwotrials.Adherencevaried
between 68% and 100%, with seven out of eight trials
reporting adherence of 80-100%.
Fall prevention with oral supplemental vitamin D
In the eight randomised controlled trials, the pooled
relative risk for any dose of vitamin D preventing a
fall was 0.87 (95% CI 0.77 to 0.99). However, hetero-
geneity in results was seen among studies (Q test:
P=0.05), although this was resolved after stratifying
trials by daily dose (200-600 IU v 700-1000 IU).
The pooled relative risk for the seven studies with
700-1000IUsupplementalvitaminDaday(1921indi-
viduals) was 0.81 (95% CI 0.71 to 0.92) suggesting that
a high dose of vitamin D a day reduced the risk of a
person falling by 19% (table 2, fig 2). The pooled risk
difference for the high dose was 9.4% (95% CI 5.1% to
13.7%; P<0.0001), so the number needed to treat was
11 (95% CI 7 to 20) for a treatment duration of
2-36 months.
Thepooledrelativeriskforthetwotrialswithadose
of less than 700 IU (200-600 IU) vitamin D a day was
1.10 (95% CI 0.89 to 1.35; Q test: P=0.42) indicating
thatlessthan700IUvitaminDadaydidnotreducefall
risk (table 3, fig 2).
Achieved serum 25(OH)D concentrations of 60
nmol/lormoreresultedina23%fallreduction(pooled
relative risk 0.77, 95% CI 0.65 to 0.90), whereas con-
centrations of less than 60 nmol/l had no effect on
number of falls (pooled relative risk 1.35, 95% CI
0.98 to 1.84).
Figure 3 shows the relationship between vitamin D
andfalls,andsuggeststhatfallpreventionbeginswitha
daily dose of 700 IU supplemental vitamin D. This
threshold was confirmed in a meta-regression of 2426
Table 2 |Primary pooled analysis and primary subgroup analyses for high doses of supplemental vitamin D (700-1000 IU) and the prevention of falls
Study (daily dose of vitamin D)
Number of
participants
Number of
fallers/
total
treated
Number of
fallers/
total
control
Effect
relative
risk
Lower 95%
CI
Upper 95%
CI
Q test P
value I2
Fall
reduction
P value:
difference
between
subgroups
Broe et al, 2007
w1 (800 IU D2) 48 5/23 11/25 0.49 0.21 1.16 ——— —
Bischoff-Ferrari et al, 2006
w2 (700 IU D3) 445 107/219 124/226 0.89 0.74 1.07 ——— —
Prince et al, 2008
w3 (1000 IU D2) 302 80/151 95/151 0.84 0.69 1.02 ——— —
Flicker et al, 2005
w4 (1000 IU D2) 625 170/313 185/312 0.92 0.80 1.05 ———
Pfeifer et al, 2008
w5 (800 IU D3) 242 48/121 76/121 0.63 0.49 0.81 ——— —
Bischoff et al, 2003
w6 (800 IU D3) 122 14/62 18/60 0.75 0.41 1.37 ——— —
Pfeifer et al, 2000
w7 (800 IU D3) 137 11/70 19/67 0.55 0.29 1.06 ——— —
Primary pooled analysis 1921 435/959 528/962 0.81 0.71 0.92 0.12 41% -19% —
Primary subgroup analyses
D3 only (w2,w6,w5,w7) 946 180/472 237/474 0.74 0.58 0.93 0.12 49% -26%
0.28
D2 only (w1
(800),w3,w4) 975 255/487 291/488 0.88 0.77 1.00 0.32 12% -12%
Men only (w1
(800),w2) 211 51/105 52/106 0.99 0.75 1.31 0.58 0% -1%
0.34
Women only* 1468 336/733 400/735 0.85 0.76 0.95 0.36 9% -15%
D3 women (w2,w6,w7) 505 84/253 112/252 0.78 0.63 0.95 0.55 0% -22%
0.27
D2 women (w1
(800),w3,w4) 963 252/480 288/483 0.87 0.74 1.03 0.21 35% -13%
Age 65-79 and/or independent (w2,w3,w5,w7) 1126 246/561 314/565 0.77 0.65 0.93 0.10 52% -23%
0.46 Age 80+ and/or institutionalised (w1
(800),w4,
w6)
795 189/398 214/397 0.86 0.70 1.07 0.32 13% -14%
Less than 12 months’ treatment duration
(w1
(800),w6,w7)
307 30/155 48/152 0.62 0.42 0.91 0.67 0% -38%
0.07
At least 12 months’ treatment duration (w2,w3,
w4,w5)
1614 305/804 480/810 0.83 0.72 0.96 0.09 56% -17%
MaineffectvitaminD(w1
(800),w3,w4,w5,w6,w7) 1476 327/740 404/736 0.77 0.65 0.92 0.09 48% -23% —
Subgroups with at least two available trials are presented.
Q test: P<0.100 indicates heterogeneity.
I
2 estimates above 25% are considered to represent modest heterogeneity, and values above 50% represent large heterogeneity beyond chance.
*Given that the Flicker et al trial included only 5% men, we added the total study population finding of Flicker to the female subgroup.
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was found between dose and the risk of sustaining at
least one fall (beta estimate for dose: ≥700 IU v <700
IU=−0.337; P=0.02). Figure 3 also suggests that a 25
(OH)D concentration of 60 nmol/l is required for fall
prevention.Thispossibilitywaslikewiseconfirmedby
a meta-regression of 1447 individuals (two trials did
not provide25(OH)Ddata
w4 w8), whichindicated a sig-
nificant inverse relationship between 25(OH)D serum
concentrationandthe riskofsustainingatleastonefall
(betaestimatefor25(OH)Dconcentration:≥60nmol/l
v <60 nmol/l=−0.586; P=0.005).
Primary subgroup analyses with trials assessing high doses
of supplemental vitamin D
In subgroup analyses of the trials that assessed a high
dose of supplemental vitamin D (700-1000 IU), the
pooled relative risk reduction was 12% in trials that
used vitamin D2 compared with 26% for trials that
used vitamin D3 (P=0.28; table 2). The combined
effect of calcium plus vitamin D compared with pla-
cebo in one study showed a relative risk reduction of
19%.
w2 The main effect of vitamin D, either vitamin D
compared with placebo or vitamin D plus calcium
compared with calcium only, was tested in six studies.
The pooled relative risk reduction for these six studies
was 23% (relative risk 0.77, 95% CI 0.65 to 0.92); thus,
the main effect of vitamin D may not depend on addi-
tional calcium supplementation. The effect of vitamin
D in women was tested in six studies (n=1468), which
had a pooled relative risk reduction of 15% compared
with 19% in men and women combined. Data on men
from two trials (n=211) were limited.
w1 w2 Treatment
duration did not modulate the effect of vitamin D sig-
nificantly: fall reduction was 38% with a treatment
duration of less than 12 months in three small trials
(relative risk 0.62, 95% CI 0.42 to 0.91) compared
with 17% with a treatment duration of 12 months or
more in four larger trials (relative risk 0.83, 95% CI
0.72to0.96;P=0.07).Thebenefitsof700-1000IUvita-
minDadayonriskoffallswerepresentinbothambu-
latoryandinstitutionalisedolderindividuals,aswellas
in trials with a mean age 65-79 years or higher.
Sensitivity analysis of supplemental vitamin D
Inasensitivityanalysis,weexaminedtheeffectsizefor
supplemental vitamin D when including studies
meeting less stringent quality criteria. Seven studies
were identified for the sensitivity analysis,
w9-w15 six
through our MeSH term search and one in the
abstracts of the American Society for Bone and
Mineral Research (table 4).
w12 Three of these trials
Table 3 |Primary pooled analysis for low doses of supplemental vitamin D (<700 IU) and the prevention of falls
Study (daily dose of vitamin D)
Number of
participants
Number of
fallers/total
treated
Number of
fallers/total
control
Effect
relative risk
Lower
95% CI
Upper
95% CI
Q test
P value I2 Fall reduction
Broe et al, 2007
w1(200) (200 IU D2) 51 15/26 11/25 1.31 0.76 2.27 —— —
Broe et al, 2007
w1(400) (400 IU D2) 50 15/25 11/25 1.36 0.79 2.35 —— —
Broe et al, 2007
w1(600) (600 IU D2) 50 15/25 11/25 1.36 0.79 2.35 —— —
Graafmans et al, 1996
w8 (400 IU D3) 354 62/177 66/177 0.94 0.71 1.24 —— —
Primary pooled analysis
(w1
(200,400,600),w8)
505 107/253 99/252 1.10 0.89 1.35 0.42 0% +10% (ns)
Q test: P<0.100 indicates heterogeneity.
I
2 estimates above 25% are considered to represent modest heterogeneity, and values above 50% represent large heterogeneity beyond chance.
ns=not significant.
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Fig 3 |Fall prevention by dose and achieved 25(OH)D
concentrations. Circles represent relative risks and error bars
represent 95% confidence intervals. Trendline is based on
series of effect sizes (circles). There were three trials with 800
IU D3,
w5 w6 w7 so the effect size for 800 IU D3 is the pooled
result from these three trials. Likewise, the effect size for
1000 IU D2 is the pooled result from the two trials with 1000
IU D2.
w3 w4 We have listed the same dose D2 and D3 separately
in the graph to account for their potential different impact on
fall reduction. As there were two data points from the Broe et
al trial that reached 48 nmol/l,
w1 two trials that reached 60
nmol/l,
w1 w3 and two trials that reached 66 nmol/l,
w6 w7 we
pooled each of the sets. On the basis of visual inspection of
figure 3, the benefits of vitamin D for fall risk started at a dose
of 700 IU a day
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insufficient assessment of falls,
w9-w11 with incomplete
fall assessment for the entire trial period in two stu-
dies.
w9 w10 Three trials had an open study design and
were not blinded,
w12 w13 w14 and one trial enrolled
patients in unstable health states.
w15
The pooled effect of all 15 eligible trials including
17786 individuals of any dose and any quality fall
assessment suggested a non-significant 7% fall reduc-
tion with vitamin D (relative risk 0.93, 95% CI 0.87 to
1.01). However, variation among the 15 trials was lar-
ger than expected (Q test: P=0.009).
After adding the seven randomised controlled trials
thatdidnotmeetourcriteriafortheprimaryanalysisto
the seven trials originally included the primary analy-
sis, the pooled relative risk for the high dose of supple-
mental vitamin D (700-1000 IU vitamin D a day) was
0.92 (95% CI 0.85 to 0.99; total 17281 individuals;
table 5). However, variation among the 14 trials was
larger than expected (Q-test: P=0.006), suggesting that
adding the lower quality trials to the analysis intro-
duces heterogeneity.
Trials of oral active forms of vitamin D
We found two randomised controlled trials of active
forms of vitamin D that met our inclusion criteria
(table 6).
w16 w17 Falls were addressed as a primary out-
come measure in both studies. No additional trials
were identified for a sensitivity analysis. The two trials
included 624 individuals with a mean age of 73 years,
70%ofwhomwerewomen.Inbothstudies,patientsin
the treatment group were more likely to experience
hypercalcaemia (up to 3 mmol/l) than were those in
the control group. The incidence of hypercalcaemia
was twice as frequent in the treatment group as in the
placebogroupinonetrial(12%v6%),
25withoutdetails
in the other.
26 The pooled relative risk for fall preven-
tion for active forms of vitamin D was 0.78 (95% CI
0.64 to 0.94), and active forms of vitamin D reduced
the risk of falls by 22% (table 7).
Fall prevention with active forms of vitamin D compared
with high dose supplemental vitamin D
The pooled relative risk for fall prevention of 0.78 for
active forms of vitamin D was similar to the pooled
relative risk of 0.81 for high doseof supplemental vita-
minD.Theratioofthetwoeffectsizes(pooledrelative
risk supplemental vitamin D/pooled relative risk
active forms of vitamin D) was 1.04 (95% CI 0.84 to
1.31), suggesting that active forms and standard forms
of vitamin D have statistically indistinguishable effects
on fall prevention.
Test for publication bias
We found noevidence for publication bias in the eight
supplemental vitamin D trials, according to both
Begg’s test and Egger’s test.
24 Although the Begg’s
test funnel plot indicated a potential absence of nega-
tive studies with small sample sizes, a trim and fill ana-
lysis did not confirm this possibility.
2728
Table 4 |Trials of supplemental vitamin D excluded from the primary analyses but included in sensitivity analyses
Source
Reason for
exclusion
Number of
participants
Age (years;
mean (SD)) Sample population
Treatment
(daily dose) Adherence
Studyduration
(months)
25(OH)D serum concentration
(mmol/l; mean (SD))
Treatment
group Control group
Grant et al,
2005
w9
Insufficient fall
assessment
5292
(4481 women,
811 men)
77 (6) Individuals who
were mobile before
developing a low
trauma fracture
800 IU vitamin D3
with or without
1000 mg calcium
(calcium carbonate)
47% 24 38 (16) to 62
(19.5) at
12 months
38 (16) to 45.8
(18) at
12 months
Trivedi et al,
2003
w10
Insufficient fall
assessment
2686
(2037 men,
649 women)
75 (5) Community dwelling
individuals
800 IU vitamin D3
(100 000 IU every
4 months) or
placebo
80% 60 74.3 (20.7) at
48 months
53.4 (21.1) at
48 months
Chapuy et al,
2002
w11
Insufficient fall
assessment
583 women 85 (7) Ambulatory
individuals living in
apartment houses
for elderly persons
800 IU vitamin D3 +
1200 mg calcium
(tri-calcium
phosphate) or
placebo
95% 24 21.3 (13.3) to
77.5 at
24 months
22.8(17.3)to15
frombargraphat
24 months
Kärkkäinen et al,
2007
w12
Open study
design
3432 women 67 Community dwelling
individuals
800 IU vitamin D3 +
1gcalciumorcontrol
group (no placebo)
Adherence not
stated
36 Not done Not done
Law 2 et al,
006
w13
Open study
design
3717
(2788 women,
929 men)
85 Patients living in
residential
accommodation
1100 IU vitamin D2
(100 000 IU
ergocalciferol every
3 months) or no
treatment (no
placebo)
Adherence not
stated
10 47 (35-102) to
74 (52-110) at
3 months
Not done
Harwood et al,
2004
w14
Open study
design
76 women 82 (67-92) Patients in
rehabilitationwards,
previously
community dwelling
800 IU vitamin D3 +
1gcalciumorcontrol
group (no placebo)
Adherence not
stated
12 30 (6-75), to 50
at 12 months
30(12-64),to27
at 12 months
Latham et al,
2003
w15
Patients in
unstable health
243
(129 women,
114 men)
80 (77-81) Patients in acute
care for any reason
1600 IU vitamin D2
(300000IUassingle
dose) or placebo
100% 6 37.5 (35-45) to
60 at 3 months
47.5(40-52.5)to
47.5at3months
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Inthismeta-analysis ofeightdoubleblind randomised
controlled trials, the efficacy of supplemental vitamin
D for fall prevention depended on dose and achieved
25(OH)D concentrations among individuals aged
65 years and older. No fall reduction was observed
for a daily dose of less than 700 IU vitamin D or
achieved serum 25(OH)D concentrations below 60
nmol/l. Daily vitamin D doses in the range of 700 IU
to 1000 IU or achieved serum concentrations between
60 nmol/l and 95 nmol/l reduced the risk of falling by
19%. Given the absence of data beyond these benefi-
cial ranges, our analyses don’t preclude the possibility
that higher doses of vitamin D or higher achieved 25
(OH)D concentrations would have been even more
efficient in reducing falls. At the high dose range of
700 IU to 1000 IU a day, the benefit of vitamin D was
not significantly affected by type of supplemental vita-
minD,gender,age,orlevelofindependence.Notably,
fall prevention with a high dose might not depend on
additional calcium supplementation and was attained
with treatment for less than 12 months (2-5 months).
The benefit was sustained for 12-36 months.
Animportantriskfactorforfallsismuscleweakness,
which is a prominent feature of the clinical syndrome
of vitamin D deficiency and could plausibly mediate
fracture risk through increasing susceptibility to
falls.
29 Binding of vitamin D to its nuclear receptor in
muscle tissue may lead to de novo protein
synthesis,
2930 a benefit that appears to precede the
effect of vitamin D on bone.
2
Comparison with other studies
Our findings confirm those in an earlier meta-analysis
onfallsfrom2004,
10which showedthatany vitaminD
reduced falls in older individuals by 22%. Of three
trialswithsupplementalvitaminDincludedinthisear-
lier meta-analysis, one trial of 400 IU vitamin D a day
showed a neutral effect,
w8 whereas two trials with 800
IU a day suggested a beneficial effect on risk of falls
(odds ratio 0.65, 95% CI 0.40 to 1.00).
w6 w7 Since then,
fivedoubleblindtrialswithsufficientqualityfallassess-
ment have been performed.
w1 w2 w3 w4 w5 Our meta-
analysis including these trials confirmed a benefit of
700 IU to 1000 IU vitamin D a day. Lending further
support to our findings, several double blind rando-
mised controlled trials have documented fracture pre-
ventionwith700-800IUvitaminDaday,
123132butnot
with 400 IU a day.
33-35
We found a 38% reduction in the risk of falling for
the high dose range of vitamin D with treatment for
2-5 months, and a sustained 17% fall reduction with
treatment for 12-36 months. Indirect support for a
rapid and sustained effect of vitamin D on falls comes
from the large fracture trial by Chapuy and
colleagues.
36 Although falls were not assessed in this
trial,supplementationmostlikelyreducedthenumber
of falls, leading to the reduction in fracture risk appar-
ent after six months.
Fall reduction was assessed as one of the end points
in a 2007evidencereportonvitamin Dcommissioned
by the United States Department of Health and
Human Services.
37 The authors combined nine
blinded and two open design trials (n=13888) of any
oral dose of vitamin D (D2 and D3) with or without
calcium compared with calcium or placebo. Their
pooledresultsuggestedanon-significant8%reduction
in falls with vitamin D (odds ratio0.92, 95% CI0.85 to
1.00). Heterogeneity by dose was not detected. The
result of the evidence report is consistent with our sen-
sitivityanalysisofall15eligibletrialsregardlessofvita-
min D dose and quality of fall assessment: we found a
non-significant 7% fall reduction with vitamin D in
17786 individuals. Variation among the 15 trials was
larger than expected (Q test: P=0.009), however, even
for the high dose sensitivity analysis (Q test: P=0.006).
Table 5 |Sensitivity analysis of the seven high dose trials from the primary analysis and the seven eligible high dose trials that did not meet the criteria for
the primary analysis
Study (daily dose of vitamin D)
Number of
participants
Number of
fallers/total
treated
Number of
fallers/total
control
Effect
relative risk
Lower
95% CI
Upper
95% CI
Q test
P value I2 Fall reduction
Pooled primaryanalysis of the seven
high dose trials (w1
(800),w2,w3,w4,
w5,w6,w7)
1921 435/959 528/962 0.81 0.71 0.92 0.12 41% -19%
Sensitivity analysis including the seven high dose trials that did not meet criteria for primary analysis
Grant et al, 2005
w9 (800 IU D3) 5292 380/2649 381/2643 1.00 0.87 1.14 —— —
Trivedi et al, 2003
w10 (800 IU D3) 2038 254/1027 261/1011 0.96 0.83 1.11 —— —
Chapuy et al, 2002
w11 (800 D3) 583 251/393 118/190 1.03 0.90 1.17 —— —
Kärkkäinenetal,2007
w12(800IUD3) 3432 180/1718 209/1714 0.86 0.71 1.04 —— —
Law et al, 2006
w13 (1100 IU D2) 3717 770/1762 833/1955 1.03 0.95 1.10 —— —
Harwood et al, 2004
w14 (800 IU D3) 76 7/39 13/37 0.51 0.23 1.11 —— —
Latham et al, 2003
w15 (1600 IU D2) 222 64/108 60/114 1.13 0.89 1.42 —— —
Pooled sensitivity analysis (w1
(800),
w2,w3,w4,w5,w6,w7,w9,w10,w11,
w12,w13,w14,w16)
17 281 2341/8655 2403/8626 0.92 0.85 0.99 0.006 56% -8%
Q test: P<0.100 indicates heterogeneity.
I
2 estimates above 25% are considered to represent modest heterogeneity, and values above 50% represent large heterogeneity beyond chance.
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found a 12% reduction in falls by pooling four trials
irrespective of their vitamin D dose or quality of fall
assessment.
38 Our analysis of five trials with sufficient
quality fall assessment showed that high doses of vita-
min D3 reduced falls by 26%.
We addressed the additional importance of calcium
in our primary analysis of high dose trials and docu-
mented a 23% fall reduction on the basis of results
from six high quality trials of vitamin D alone
compared with placebo or vitamin D plus calcium
comparedwithcalcium.
w1 w3-w7VitaminDincombina-
tionwithcalciumcomparedwithplaceboreducedfalls
by 19% according to limited data from one trial.
w2
Thus, the effect of 700-1000 IU vitamin D a day on
falls may not depend on additional calcium supple-
mentation, which could be explained by the calcium
sparing effect of vitamin D.
3940
Active forms of vitamin D reduced falls by 22% and
thehighdosesupplementalvitaminDreducedfallsby
19%,suggestingnodifferenceinefficacybetweenthese
alternatives in unselected older persons. However, the
efficacy data for active forms of vitamin D was drawn
from relatively few studies. In addition, active forms
cost more and have a higher risk profile, so we believe
adequate dosing of supplemental vitamin D should be
preferred. Importantly, the efficacy of active forms of
vitamin D adds to the evidence that improved vitamin
D status reduces the risk of falling in older individuals.
Limitations of study
As with all meta-analyses, this review has the potential
for publication bias. However, we found no evidence
for publication bias using the Begg’s test and the
Egger’s test with all eight trials.
24 Although the Begg’s
test funnel plot suggested a possible absence of nega-
tive studies with small sample sizes, the trim and fill
analysis did not confirm this suggestion.
2728 With
respect to trial quality, our primary analysis was
restricted to trials with a double blind design and suffi-
cient quality fall assessment to address the efficacy of
vitaminDforfallprevention.Inoursensitivityanalysis
that included additional trials with an open study
design or insufficient fall assessment, study variation
was larger than expected for the pooled result from
all 15 trials. Even within the 14 high dose trials, varia-
tion between trials was larger than expected, support-
ing our pre-defined strategy of focusingon fall efficacy
from double blind trials with sufficient fall assessment.
Implications for future research
Wefoundagreaterfallreductioninstudieswithamax-
imum vitamin D daily dose of 1000 IU a day than in
studies with lower doses; therefore, higher doses may
beevenmoreeffective.Suchdosesshouldbeexplored
in future research to optimise the fall prevention ben-
efit with vitamin D.
Conclusions
Doses of 700 IU to 1000 IU supplemental vitamin D a
day could reduce falls by 19% or by up to 26% with
vitamin D3. This benefit may not depend on additional
calcium supplementation, was significant within
2-5 months of treatment, and extended beyond
12 months of treatment. Conversely, our results do
not support the clinical use of vitamin D doses below
700 IU a day for the prevention of falls among older
individuals. A 25(OH)D concentration of at least 60
nmol/l is required for fall prevention; therefore, a
daily intake of at least 700 IU supplemental vitamin D
iswarrantedinallindividualsage65andolder.Notably,
goodadherenceisessentialastheeffectofvitaminDon
falls will not be proportional below 700 IU a day.
Furthermore, it is possible that greater benefits may be
Table 6 |Randomised controlled trials of active forms of vitamin D included in the primary analyses
Source
Number of
participants
Age (years;
mean (SD))
Sample
population
Treatment (daily
dose) Adherence
Study
duration
(months)
25(OH)D serum concentration
(mmol/l; mean (SD))
Treatment group Control group
Dukas et al, 2004
w16 278
(191 women,
187 men)
75 (5) Community
dwelling
individuals
1 μg1 α-
hydroxyvitamin D3
or placebo
84% among women,
87% among men
9 78.0 (21.6) to 60.7
(19.7) at 9 months
70.8(26.8)atbaseline
at 9 months
Gallagher et al,
2001
w17
246 women 71 (4) Community
dwelling
individuals
0.5 μg1 , 2 5 -
dihydroxyvitamin D3
or placebo
70% 36 74.8 (29.0) to 55.5
(20.5) at 36 months
80.5 (27.4) to 63.2
(19.7) at 36 months
Table 7 |Primary pooled analysis for active forms of vitamin D and the prevention of falls
Study (daily dose of
vitamin D)
Number of
participants
Number of
fallers/total
treated
Number of
fallers/total
control
Effect
relative
risk
Lower
95% CI
Upper
95% CI
Q test P
value I2
Fall
reduction
Dukas et al, 2004
w16
(1α-hydroxyvitamin D3)
378 40/192 46/186 0.84 0.58 1.22 —— —
Gallagher et al, 2001
w17
(1,25-dihydroxyvitaminD3)
246 59/123 78/123 0.76 0.60 0.95 —— —
Pooled primary analysis
(w16,w17)
624 99/315 124/309 0.78 0.64 0.94 0.63 0% -22%
Q test: P<0.100 indicates heterogeneity.
I
2 estimates above 25% are considered to represent modest heterogeneity, and values above 50% represent large heterogeneity beyond chance.
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D2. Finally, active forms of vitamin D do not appear to
be more effective than 700-1000 IU of supplemental
vitamin D for fall prevention in older persons.
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